You have 9 free searches left this month | to do more

pasireotide

Pasireotide is a drug used to treat Acromegaly, Cushing's Disease, Neuroendocrine Tumors, and other conditions. Pasireotide is being actively studied in 2 studies and prior, has been studied in 21.

Top SponsorsTop SitesTop Investigators
Novartis PharmaceuticalsNovartis Investigative SiteAnthony Sung, MD
Emory UniversityStanford University Medical Center Stanford Cancer Center (3)Bassel El-Rayes
Alliance Pour La Recherche en CancerologieBaylor College of MedicineElisabeth Heath
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Pasireotide Treatment for Neuroendocrine Tumor - 2016
Withdrawn
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • (no location specified)
2022-02-17
Feb 17, 2022
A
Pasireotide in Prevention of GI Toxicity - 2019
Completed
Has Results
  • Hematological Malignancies
  • Pasireotide
  • Boston, Massachusetts
  • +1 more
2021-10-19
Oct 19, 2021
H
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment - 2021
Completed
  • Enterostomy
  • Pasireotide
  • Placebo
  • Amiens, France
  • +13 more
2022-03-23
Mar 23, 2022
U
Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia - 2017
Completed
  • Hyperinsulinemic Hypoglycemia
  • Post Gastrointestinal Tract Surgery Hypoglycaemia
  • Pasireotide
  • Aurora, Colorado
    University of Colorado Denver
2021-09-27
Sep 27, 2021
E
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer - 2019
Completed
Has Results
  • Thyroid Cancer
  • Atlanta, Georgia
  • +2 more
2021-02-15
Feb 15, 2021
N
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly - 2013
Completed
Has Results
  • Acromegaly
  • Pasireotide
  • Los Angeles, California
  • +9 more
2021-09-01
Sep 1, 2021
N
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Completed
  • Hepatic Cirrhosis
  • Alcoholism
  • Pasireotide
  • Richmond, Virginia
  • +3 more
2020-12-17
Dec 17, 2020
B
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer - 2017
Completed
Has Results
  • Adenocarcinoma of the Prostate
  • +3 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
2021-03-02
Mar 2, 2021
H
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Active, not recruiting
  • Pancreatic Fistula
  • Pancreatic Neoplasms
  • Helsinki, Finland
    Helsinki University Central Hospital
2020-08-21
Aug 21, 2020
M
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Available
  • Congenital Hyperinsulinism
  • Pasireotide
  • Bronx, New York
    Montefiore Medical Center
2021-07-19
Jul 19, 2021
N
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease - 2013
Completed
Has Results
  • Cushing Disease
  • Pasireotide
  • Boston, Massachusetts
  • +7 more
2021-05-06
May 6, 2021
N
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease - 2013
Completed
  • Carcinoid Tumor
  • Acromegaly
  • Pasireotide
  • Los Angeles, California
  • +16 more
2020-12-17
Dec 17, 2020
R
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Active, not recruiting
  • Cushing's Disease
  • +8 more
  • La Jolla, California
  • +93 more
2020-10-30
Oct 30, 2020
H
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 - 2020
Completed
  • Healthy
  • Nottingham, United Kingdom
    Quotient Sciences
2020-10-26
Oct 26, 2020
E
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases - 2018
Completed
  • Neuroendocrine Tumors
  • Pasireotide
  • +2 more
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
2018-10-16
Oct 16, 2018
S
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer - 2012
Terminated
Has Results
  • Castrate Resistant Prostate Cancer
  • +2 more
  • Pasireotide
  • +2 more
  • New Haven, Connecticut
  • +1 more
2018-04-23
Apr 23, 2018
C
SOM230 Ectopic ACTH-producing Tumors
Withdrawn
  • Ectopic ACTH Syndrome
  • Pasireotide
  • Los Angeles, California
    Cedars-Sinai Medical Center
2018-01-24
Jan 24, 2018
N
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly - 2017
Completed
Has Results
  • Acromegaly
  • Pasireotide
  • +2 more
  • Ann Arbor, Michigan
  • +59 more
2018-04-02
Apr 2, 2018
A
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer - 2013
Completed
  • Breast Cancer
  • PASIREOTIDE
  • PLACEBO
  • Paris, France
  • +1 more
2017-01-24
Jan 24, 2017
S
Pasireotide Therapy in Patients With Nelson's Syndrome - 2015
Terminated
  • Nelson Syndrome
  • Pasireotide
  • London, United Kingdom
  • +3 more
2016-11-01
Nov 1, 2016
N
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly - 2016
Completed
Has Results
  • Acromegaly
  • Los Angeles, California
  • +94 more
2017-06-05
Jun 5, 2017
U
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas - 2012
Completed
Has Results
  • Non-functioning Pituitary Adenomas
  • Prolactinomas
  • Rio de Janeiro, RJ, Brazil
    Endocrinology Section - Hospital Universitário Clementino Fraga
2016-07-21
Jul 21, 2016
U
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma - 2015
Completed
Has Results
  • Advanced Adult Hepatocellular Carcinoma
  • Tampa, Florida
  • +2 more
2016-03-08
Mar 8, 2016
R
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure - 2015
Completed
  • Angiodysplasia
  • Pasireotide
  • Placebo
  • Paris, France
    Société Française d'Endoscopie Digestive (SFED)
2015-12-04
Dec 4, 2015
N
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease - 2014
Completed
Has Results
  • Cushing's Disease
  • Pasireotide
  • Stanford, California
  • +67 more
2016-02-05
Feb 5, 2016